Seagen Inc. with ticker code (SGEN) now have 7 market analysts covering the stock. The analyst consensus now points to a rating of ‘buy’. The range between the high target price and low target price is between $229.00 and $229.00 with the average target price sitting at $229.00. Given that the stocks previous close was at $228.90 this is indicating there is a potential upside of .0%. The 50 day moving average now sits at $217.43 and the 200 moving average now moves to $204.65. The total market capitalization for the company now stands at 43.15B. The stock price for the company is currently $228.74 USD
The potential market cap would be $43,173,629,177 based on the market consensus.
The company has a dividend yield of 5.95%. Other points of data to note are a P/E ratio of -, revenue per share of $12.29 and a -12.94% return on assets.
Seagen Inc. is a biotechnology company that develops and commercializes targeted therapies to treat cancer. The Company is engaged in commercializing ADCETRIS, or brentuximab vedotin, for the treatment of certain CD30-expressing lymphomas; PADCEV, or enfortumab vedotin-ejfv, for the treatment of certain metastatic urothelial cancers; TUKYSA, or tucatinib, for the treatment of certain metastatic human epidermal growth factor receptor 2 (HER2) -positive breast and colorectal cancers, and TIVDAK, or tisotumab vedotin-tftv, for the treatment of certain metastatic cervical cancers. It is also advancing a pipeline of novel therapies for solid tumors and blood-related cancers designed to address unmet medical needs and improve treatment outcomes for patients. Its programs including ADCETRIS, PADCEV and TIVDAK, are based on the Company’s antibody-drug conjugate (ADC) technology that utilizes the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells.
